Capreomycin is a macrocyclic peptide antibiotic that was initially isolated from the bacterium Streptomyces capreolus. Capreomycin binds to bacterial ribosomes and inhibits protein synthesis and is considered bacterostatic rather than bacterocidal. Capreomycin additionally has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Clinically, capreomycin is used as a secondary agent in the treatment of tuberculosis in combination with other antituberculosis agents, and usually for multidrug resistant mycobacterial infections. Capreomycin is available as lyophilized powder for suspension in vials of 1 gram for deep intramuscular or intravenous injection under the trade name of Capastat.
